UroGen Pharma Ltd.
About UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $109.8M
- Net income
- -$153.5M
- Total assets
- $200.5M
- Market cap
- $1.3B
- Gross margin
- 88.7%
- Operating margin
- -113.7%
- Net margin
- -139.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $109.8M
- Cost of revenue
- $12.4M
- Gross profit
- $97.3M
- Operating expenses
- $222.2M
- Operating income
- -$124.9M
- Income tax
- $78.0K
- Net income
- -$153.5M
- EPS (basic)
- $-3.19
Balance sheet
- Total assets
- $200.5M
- Current assets
- $186.0M
- Total liabilities
- $305.9M
- Current liabilities
- $46.4M
- Shareholders’ equity
- -$105.5M
Cash flow
- Operating cash flow
- -$162.4M
- Investing cash flow
- $61.6M
- Financing cash flow
- $39.9M
- Net cash flow
- -$61.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- Shares outstanding
- 48.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 4, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $153.5M in FY2025.
- Revenue grew 129% from FY2021 to FY2025.
- Gross margin of 88.7%, net margin -139.8%.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review UroGen Pharma Ltd..
Write a review
News about UroGen Pharma Ltd.
News & sentiment via Polygon.io
